No Data
No Data
Chempartner Pharmatech Ties Up With Jinan University's National Key Laboratory to Develop Drugs
Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 36% Jump Looks Justified
Chempartner Pharmatech Ties Up With Malaysian University, Pharmaceutical Firm for Drug Research
chempartner pharmatech (300149.SZ): Currently, in the ADC projects we are collaborating on, more than 30 ADC molecules have entered clinical or PCC research stage.
On September 12, 2024, Chempartner Pharmatech (300149.SZ) held a performance briefing, regarding the question "I heard that the company's ADC Global Innovation Center has been launched, what are the specific details?" The company stated that Chempartner Pharmatech's ADC Global Innovation Center covers antibody development starting from drug targets, drug chemistry, bioconjugation and characterization, in vivo pharmacology and efficacy, pharmacokinetics, and early-stage toxicity studies. It provides integrated ADC drug development services from antibody research and development to IND application. The company has collaborated with multiple well-known pharmaceutical companies domestically and internationally, completing hundreds of early-stage ADC development projects and assisting clients.
Chempartner Pharmatech (300149.SZ): has applied AI technologies such as Alphafold to drug design, antibody engineering, and other pharmaceutical research and development businesses.
格隆汇September 12th丨Chempartner Pharmatech (300149.SZ) held a performance briefing on September 12, 2024, regarding the "Company's ai pharmaceutical situation and planning?". The company stated that it has applied AI technologies such as Alphafold to drug design, antibody engineering, and other drug research and development business, and continues to focus on the application of artificial intelligence technology in new areas of pharmaceutical research and development. As a CRO company with more than 20 years of pharmaceutical service experience, the company has accumulated rich experience and has inherent advantages in AI pharmaceuticals. The company is actively exploring new technologies in CRO+AI research and development to enhance
Chempartner Pharmatech (300149.SZ): Signed a strategic cooperation framework agreement with UKM and PMSB.
Gelonghui, September 12th, Chempartner Pharmatech (300149.SZ) announced that the company recently signed a "Strategic Cooperation Framework Agreement" with Universiti Kebangsaan Malaysia (UKM) and Pharma Medical Sdn Bhd. (PMSB). Based on the principles of resource sharing, complementary advantages, and win-win cooperation, the parties will collaborate in the field of drug discovery and development. The company will jointly establish a laboratory with UKM and leverage the company's industry expertise.
No Data
No Data